PLSE logo

PLSE
Pulse Biosciences Inc

2,059
Mkt Cap
$1.73B
Volume
175,501.00
52W High
$27.98
52W Low
$12.56
PE Ratio
-22.62
PLSE Fundamentals
Price
$26.12
Prev Close
$24.95
Open
$24.65
50D MA
$21.61
Beta
1.48
Avg. Volume
253,844.61
EPS (Annual)
-$1.08
P/B
25.68
Rev/Employee
$3,017.24
$852.13
Loading...
Loading...
News
all
press releases
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors...
Yahoo! Finance: News·3d ago
News Placeholder
More News
News Placeholder
ATM Equity Purchases by Pulse Biosciences Co-Chairmen Total Approximately $13.3 Million
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced its Co-Chairmen of the Board, Robert Duggan...
Business Wire·8d ago
News Placeholder
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary nanosecond pulsed field ablation (nsPFA) energy, today announced plans to participate in the upcoming BofA...
Business Wire·12d ago
News Placeholder
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?
Pulse Biosciences (PLSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·13d ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Announces Quarterly Earnings Results, Beats Estimates By $0.05 EPS
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) issued its earnings results on Monday. The company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.05...
MarketBeat·16d ago
News Placeholder
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Pulse Biosciences (PLSE) delivered earnings and revenue surprises of +15.63% and -19.80%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16d ago
News Placeholder
Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse technology using proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced business updates and...
Business Wire·16d ago
News Placeholder
Pulse Biosciences (PLSE) Expected to Announce Quarterly Earnings on Thursday
Pulse Biosciences (NASDAQ:PLSE) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-pulse-biosciences-inc-stock...
MarketBeat·20d ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Shares Down 7.9% - What's Next?
Pulse Biosciences (NASDAQ:PLSE) Trading Down 7.9% - Time to Sell...
MarketBeat·21d ago
News Placeholder
Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse Cardiac Catheter System at Heart Rhythm 2026
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse technology using proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced late-breaking...
Business Wire·25d ago
<
1
2
...
>

Latest PLSE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.